Palvella Therapeutics (PVLA) Analyst & Key Data

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts29

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$150.13

Median Target+20.58%

$181.03

Potential upside vs current price

DCF Value-96.86%

$4.71

Potential downside vs current price

Current Stock Price

$150.13

Median Target+20.58%

$181.03

Potential upside vs current price

DCF Value-96.86%

$4.71

Potential downside vs current price

Analyst Consensus

Analyst recommendation mix is not available yet.

Total Analysts29

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$150.13

Median Target+20.58%

$181.03

Potential upside vs current price

DCF Value-96.86%

$4.71

Potential downside vs current price

Current Stock Price

$150.13

Median Target+20.58%

$181.03

Potential upside vs current price

DCF Value-96.86%

$4.71

Potential downside vs current price

Palvella Therapeutics, Inc.